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 Background: Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung 
cancer (NSCLC). In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cispl-
atin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncol-
ogy clinic.
 Material/Methods: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with 
cisplatin-vinorelbine were retrospectively analyzed. Cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) were ad-
ministered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were giv-
en. All patient data, including pathological, clinical, radiological, biochemical, and hematological data, were as-
sessed retrospectively using our database system.
 Results: Our study included 97 unresectable stage III NSCLC patients who were treated with CCRT. Median age was 58 
years old (range 39–75) and 87 (89.7%) of the patients were men. ECOG performance score was 0–1 in 93 pa-
tients (95.9%). Squamous histology, the most common histology, was diagnosed in 46 patients (47.4%). Median 
follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) 
were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% 
and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and 
non-hematological grade 3–4 toxicities were seen in 13 (13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) 
patients died due to toxicity.
 Conclusions: The results of this study suggest that split-dose cisplatin may offer fewer grade III–IV toxicities without sacri-
ficing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. Similar to past 
studies, despite high response rate during CCRT, distant relapse is the major parameter that influences patient 
survival in long-term in NSCLC.
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Background
Lung cancer is the leading cause of cancer-related death among 
all types of cancers [1]. Non-small cell lung cancer (NSCLC) ac-
counts for the majority of cases and one-third of them pre-
sented at locally advanced stage [2].Concurrent chemoradio-
therapy (CCRT) has been accepted as a standard treatment 
modality for patients with unresectable stage III NSCLC dis-
ease. CCRT provides better overall survival (OS) compared to 
sequential chemotherapy followed by radiotherapy or tho-
racic radiotherapy only [3–5]. Despite the high response rate 
with CCRT, median overall survival time for these patients is 
15–25 months. The optimal chemotherapy regimen in CCRT 
has not been clearly defined. The most commonly used reg-
imens are mitomycin-vindesine and cisplatin, etoposide and 
cisplatin, paclitaxel and carboplatin, and vinorelbine and cis-
platin [3–6]. There is no phase III randomized trial comparing 
cisplatin-based regimens during CCRT and studies in the liter-
ature report similar response and survival rates.
With this study, we aimed to investigate the efficacy and toxicity 
of CCRT with split low-dose cisplatin (30 mg/m2) and vinorelbine 
(20 mg/m2) during radiotherapy and 2 additional cycles of con-
solidation therapy after CCRT with the same drugs in patients 
with inoperable stage III NSCLC followed in our oncology clinic.
Material and Methods
Patient population
We retrospectively analyzed medical records from 2006 to 2012 
of 97 patients with inoperable stage IIIA and IIIB NSCLC treated 
with concurrent chemoradiotherapy with cisplatin and vinorel-
bine. All data of the patients, including pathological, clinical, 
radiological, biochemical, and hematological data, were as-
sessed retrospectively using our database system.
Staging was determined according to the TNM classification 
seventh edition [7].This study was approved by the Baskent 
University Institutional Review Board and supported by the 
Baskent University Research Fund.
All patients had histologically confirmed of non-small cell lung 
carcinoma. PET-CT (18F-FDG) scans and cranial MRI were used 
for staging and radiotherapy planning for all patients. The de-
cision regarding mediastinal lymph node sampling was made 
by the thoracic tumor board.
Chemotherapy and radiotherapy
Cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) from periph-
eral route were administered on days 1, 8, 22, and 29 during 
radiotherapy. Two cycles of consolidation chemotherapy (total 4 
cycles) with the same drugs were given as cisplatin (80 mg/m2) 
and vinorelbine (25 mg/m2).
For thoracic radiotherapy (TRT), 3-dimensional conformal ra-
diation therapy (3D-CRT) utilizing co-registered FDG-PET-CT-
based treatment planning was delivered to all patients. Gross 
tumor volume (GTV) included all primary tumor(s) and abnor-
mally enlarged hilar or mediastinal lymph nodes greater than 
1 cm in diameter seen on CT or metabolically active areas on 
PET-CT images. Clinical target volumes (CTVs) were defined 
by adding 1-cm margins to GTVs, and elective nodal stations 
were not included in the CTV. Planning target volume-1 (PTV1) 
was created by adding an additional 1.5-cm margin to CTVs, 
and PTV2 (boost field) was defined as the GTVs plus a 1.5-
cm margin. For all patients, 3D-CRT plans were aimed to min-
imize the volume of normal lung and surrounding normal tis-
sues irradiated while providing coverage of PTVs by isodose 
surfaces between 95% and 107%. TRT was delivered through 
the anteroposterior-posteroanterior portals with customized 
multi-leaf collimators for PTV 1–46 Gy/23 fractions, followed 
by off-spinal cord oblique boost dose up to 66 Gy/33 frac-
tions for PTV 2.
Toxicity
Toxicities were graded according to the National Cancer 
Institute Common Toxicity Criteria Adverse Events (CTCAE) 
version 3.0. Patients were evaluated weekly during concur-
rent CRT and consolidation chemotherapy.
Response evaluation
Response to treatment was defined by using RECIST crite-
ria [8]. Clinical examination at every 3 months and radiologi-
cal examination at every 6 months imaging were used for pa-
tient surveillance. Types of first relapses (distant and local) 
were recorded.
Statistics
All results are presented as rate for categorical values or 
mean and median for continuous variables. Overall surviv-
al (OS) was determined as time between histological diag-
nosis and death/last control. Progression-free survival (PFS) 
was determined as time between diagnosis and progres-
sion or death. Survival curves were estimated according to 
the Kaplan-Meier method and log-rank test was used for 
univariate comparisons. Adjusted hazard ratios (HRs) and 
95% confidence intervals (95% CIs) were used for estima-
tion. All data were analyzed using SPSS version 17.0 (SPSS 
Inc, Chicago, IL) and a p value of <0.05 was considered sta-
tistically significant.
662
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS] [Index Copernicus]
Mertsoylu H. et al.: 
Concurrent chemoradiotherapy in lung cancer
© Med Sci Monit, 2015; 21: 661-666
CLINICAL RESEARCH
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 3.0 Unported License
Results
After analyzing the medical records, 97 consecutive unresect-
able stage IIIA-B NSCLC patients treated with CCRT in our cen-
tre were included into this study. Patients’ baseline characteris-
tics are shown in Table 1. Median age was 58 years old (range 
39–75), and 87 (89.7%) of the patients were men. ECOG per-
formance score was 0–1 in 93 patients (95.9%). Squamous his-
tology, the most common histology, was diagnosed in 46 pa-
tients (47.4%). There were 41 (42.3%) stage IIIA patients and 
56 (57.7%) stage IIIB patients.
Objective response rate (CR+PR) and clinical benefit rate 
(CR+PR+SD) were 75.3% and 83.5%, respectively (Table 2). 
Median follow-up time was 23.8 months (range 0.9–60). Median 
PFS and OS were 10.3 ([(95% CIs), 9.2–11.5) and 17.8 months 
([(95% CIs), 11.4–24.4) (Figures 1 and 2). When we evaluated 
No. of patients %
Age, years
 <65 78 80.4
 65+ 19 19.6
Sex
 Male 87 89.7
 Female 10 10.3
ECOG PS
 0 26 26.8
 1 67 69.1
 2 4 4.1
Smoking
 Yes 93 95.9
 No 4 4.1
Histology
 Squamous 46 47.4
 Adenocarcinoma 41 42.3
 Others 10 10.3
Comorbidities
 Yes 22 22.7
 No 75 77.3
AJCC stage
 IIIA 41 42.2
 IIIB 56 57.8
Table 1. Patient characteristics.
No. of patients %
Progressive disease 7 7.2
Stable disease 8 8.2
Partial response 55 56.7
Complete response 18 18.6
Table 2. Response rates.
Figure 1.  Kaplan-Meier progression-free survival of patients 
treated with concurrent chemoradiotherapy with split 
low-dose cisplatin-vinorelbine followed by 2 additional 
courses of consolidation chemotherapy, 10.3 months 
([(95% CIs), 9.2–11.5).
1.0
0.8
0.6
0.4
0.2
0.0
0.0 6.0 12.0 18.0 24.0 30.0 36.0
Pa
tie
nt
s p
ro
gr
es
sin
g (
%
)
Progression free survival (months)
Figure 2.  Kaplan-Meier overall survival of patients treated with 
concurrent chemoradiotherapy with split low-dose 
cisplatin-vinorelbine followed by 2 additional courses 
of consolidation chemotherapy, 17.8 months ([(95% 
CIs), 11.4–24.4).
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the 61 (62.8%) patients who relapsed, distant and local re-
lapse rates were 57.1 and 42.9%, respectively.
In the whole group, 92.8% of patients had received the planned 
therapy of CCRT and consolidation chemotherapy. The reason 
for not completing full course chemotherapy and CCRT was 
treatment related to death in 4 patients. During the study pe-
riod, 43 patients died. Response evaluation could not be done 
in 9 patients: 2 were lost during CCRT, 4 died during consolida-
tion chemotherapy, and 3 were lost to follow-up. Furthermore, 
hematological and non-hematological grade 3–4 toxicities 
were seen in 13 (13.4%) and 16 (16.5%) patients, respectively 
(Table 3). Additionally, drug extravasation occurred in 6 (6.2%) 
patients during the chemotherapy regimen, and we did hot 
compression and close follow-up. All patients recovered with-
out any sequel from extravasation.
Discussion
NSCLC is still the leading cause of cancer-associated death in 
both women and men. Despite advances in monitoring and ra-
diologic imaging techniques, most patients were diagnosis at 
advanced stage. CCRT is the standard treatment for unresect-
able stage III NSCLC patients. Data in the literature strongly 
suggest that CCRT significantly improves survival rates when 
compared to thoracic radiotherapy and sequential chemo-
radiotherapy [3–5]. Although CCRT is the standard, the best 
chemotherapy combination is not known. Randomized trials 
demonstrated that full-dose chemotherapy with cisplatin-based 
regimen improves long-term survival compared with sequential 
chemoradiotherapy, but using full-dose chemotherapy result-
ed in excessive toxicity [3,4,9,10]. There is no published phase 
III randomized trial that directly compares different combina-
tion regimens in CCRT, but cisplatin plus etoposide and week-
ly carboplatin plus paclitaxel have been most commonly used 
combination regimens with thoracic radiotherapy. These com-
binations have been demonstrated to be effective and safe 
in randomized studies [6,11–13], with reported median over-
all survival times between 15 and 23 months. Failure of loco-
regional control was reported at around 20%, and failure at 
distant sites was far more commonly reported than local re-
lapse and major cause of death [6,11].
Vinorelbine is a semi-synthetic vinca alkaloid and is the most 
active member of this group against NSCLC. The combina-
tion of cisplatin-vinorelbine was shown to be effective in ad-
vanced and adjuvant setting of NSCLC [14–16]. Phase II studies 
showed that cisplatin-vinorelbine is also an effective and safe 
radio sensitizer in CCRT, with median overall survival time be-
tween 21 and 23 months [17,18]. These studies used vinorel-
bine dose of 20 mg/m2, not the usual 25 mg/m2 dose used in 
metastatic or adjuvant settings.
With this study, we reported results of 97 unresectable stage 
III NSCLC patients treated with CCRT associated with split 
low dose of cisplatin-vinorelbine and followed by 2 cycles of 
the same drugs. Of the total, 9 patients did not receive pro-
tocol treatment. Median PFS and OS were 10.3 [(95% CIs), 
9.2–11.5)] and 17.8 months [(95% CIs), 11.4–24.4)], respec-
tively. These results were comparable with other studies in 
the literature [4–6,9–13].
PET-CT plays an important role in the evaluation of patients 
with stage III lung cancer and is recommended. When com-
pared with CT imaging, PET-CT significantly increases sensitiv-
ity and specificity of radiological staging, especially in evalua-
tion of mediastinal lymph nodes. However, in areas of endemic 
granulomatous infection, PET has been shown to increase the 
rates of false-positives in mediastinal lymph nodes. Therefore, 
positive PET-CT findings should be checked with tissue confir-
mation with invasive interventions [19,20]. PET-CT was used 
in 97 patients (100%) for clinical staging and 3D-radiotherapy 
planning. Treatment response was also evaluated by PET-CT in 
57 patients (64.4%). In this study, we actively used PET-CT for 
staging. Diagnostic mediastinoscopy was used in 14 (14.4%) 
patients for staging purposes. We believe that mediastinosco-
py should be done in every case with FDG positive mediasti-
nal lymph nodes; this is a weakness of our study. All patients 
were discussed by the multi-disciplinary board, but rejection 
of procedure by patients, technical difficulties of reaching to 
Grade 3 and 4 toxicities (CCRT)
Toxicities No. of patients %
Hematological toxicities  13 13.4
 Anemia  7 7.2
 Neutropenia  8 8.2
 Febrile Neutropenia  6 6.1
 Thrombocytopenia  2 2.0
Non-hematological toxicities  16 16.5
 Esophagitis  13 13.4
 Renal toxicity  2 2.0
 Pulmonary toxicity  6 6.1
Rate of mortality  4 4.1
 Pulmonary toxicity  2 2.0
 Febrile neutropenia  3* 3.0
Table 3.  Major toxicities during CCRT and consolidation 
chemotherapy.
* One patient also had pulmonary toxicity.
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FDG-positive lymph nodes, and having T4 tumors were major 
reasons for not doing mediastinoscopy routinely.
Median follow-up period was 23.8 months [(95%CIs 0.9–60)]. 
Median OS and PFS were 17.8 months [(95% CIs) 11.4–24.4] 
and 10.3 months [(95% CIs), 9.2–11.5], respectively. In the lit-
erature, CCRT studies reported median OS and PFS between 
12–25 and 10–15 months, respectively. In our study, 4 (4.1%) 
patients had ECOG performance of 2, and all of these patients 
were dead in less than 6 months. Although our results showed 
that our OS and PFS was at the lower edge of that in the lit-
erature, this study included patients with low performance 
scale and we think that our study truly reflects the situation 
of real clinical practice.
Objective response rate (CR+PR) and disease control rate 
(CR+PR+SD) were determined as 75.3% and 85%, respectively. 
This response rate in this study is quite close the other stud-
ies in the literature. During the follow-up period 61 (63%) pa-
tients relapsed at systemic and local site in 57.1% and 42.9%, 
respectively. This result showed that most patients with unre-
sectable stage III NSCLC have a high distant relapse rate, sys-
temic disease at diagnosis, and poor long-term survival rates. 
Because of high relapse rate at distant sites, consolidation 
chemotherapy had been added to CCRT, either with the same 
regimen or switched to another chemotherapy regimen. The 
positive effect of consolidation chemotherapy after CCRT with 
either the same or switched regimen has not been shown in 
the literature. We used the same chemotherapy regimen (cis-
platin-vinorelbine) for 2 more cycles, similar to other studies.
Completion of full planed treatment was achieved in 88 (92.8%) 
patients. The occurrence of severe hematological and non-
hematological grade III and IV toxicities were detected in 13 
(13.4%) and 16 (16.5%) patients, respectively. In the litera-
ture, no chemotherapy regimen incorporated to CCRT showed 
a clear advantage over other regimens in efficacy. A trial that 
compared cisplatin-vinorelbine, cisplatin-paclitaxel, and cispl-
atin-gemcitabine in CCRT showed similar efficacy but differ-
ent toxicity profiles of these regimens. Their conclusion was 
cisplatin-gemcitabine may have unacceptable toxicity com-
pared to other regimens [21]. Mariano et al. reported cispla-
tin-vinorelbine had less toxicity and had the highest comple-
tion rate of full treatment course in a review article [22]. We 
showed that split low-dose cisplatin-vinorelbine with CCRT 
seemed to be less toxic and that the completion rate of full 
treatment course was higher when compared to that in the 
literature. Therefore, we suggest that decreasing the cisplat-
in and vinorelbine dose and giving split dose of cisplatin may 
provide less toxicity without sacrificing efficacy.
Conclusions
The current study showed that split low-dose cisplatin-vinorel-
bine provides results similar to that in the literature regarding 
response rate and survival parameters and it may be an option 
for CCRT in patients with unresectable stage III NSCLC. We report-
ed a higher rate of treatment-related death (4 patients had per-
formance score of 2 at the basal state) and lower rates of grade 
3 and 4 hematological and non-hematological toxicities when 
compared with the literature. Furthermore, results of this study 
suggest that split low-dose cisplatin-vinorelbine may decrease 
grade III and IV toxicities during CCRT without decreasing the ef-
ficacy. Similar to past studies, despite a high response rate dur-
ing CCRT, distant relapse is the major parameter that influences 
patient survival on long-term in NSCLC. Developing more effec-
tive systemic treatment is key for long-term success in NSCLC.
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